Description Module
The Description Module contains narrative descriptions of the clinical trial, including a brief summary and detailed description. These descriptions provide important information about the study's purpose, methodology, and key details in language accessible to both researchers and the general public.
Description Module path is as follows:
Study -> Protocol Section -> Description Module
Description Module
Ignite Creation Date:
2025-12-25 @ 1:41 AM
Ignite Modification Date:
2025-12-25 @ 1:41 AM
NCT ID:
NCT00126594
Brief Summary:
This randomized phase II trial is studying sorafenib and interferon alfa-2b to see how well they work compared to sorafenib alone in treating patients with metastatic kidney cancer. Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Interferon alfa-2b may interfere with the growth of tumor cells. Sorafenib and interferon alfa-2b may also block blood flow to the tumor. Giving sorafenib together with interferon alfa-2b may kill more tumor cells.
Detailed Description:
PRIMARY OBJECTIVES:
I. Efficacy of Bay 43-9006 with or without low dose interferon by evaluating response rate in MRCC.
II. Toxicities of Bay 43-9006 with or without low dose interferon in MRCC.
SECONDARY OBJECTIVES:
I. Progression free survival. II. Duration of response. III. Overall Survival.
OUTLINE: Patients are randomized to 1 of 2 treatment arms.
Arm I: Patients receive oral sorafenib twice daily on days 1-28.
Arm II: Patients receive sorafenib as in arm I and low-dose interferon alfa-2b subcutaneously twice daily on days 1-28.
In both arms, courses repeat every 28 days in the absence of progressive disease or unacceptable toxicity.
Tissue samples are analyzed for single nucleotide polymorphisms (SNP) patterns via genotyping.
After completion of study treatment, patients are followed every 3 months.
Study:
NCT00126594
Study Brief:
Protocol Section:
NCT00126594